These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 21944002)

  • 1. Targeted therapy in refractory thyroid cancer.
    Schlumberger M;
    Eur J Cancer; 2011 Sep; 47 Suppl 3():S328-9. PubMed ID: 21944002
    [No Abstract]   [Full Text] [Related]  

  • 2. Differentiated thyroid cancers: a comprehensive review of novel targeted therapies.
    Kojic KL; Kojic SL; Wiseman SM
    Expert Rev Anticancer Ther; 2012 Mar; 12(3):345-57. PubMed ID: 22369326
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A new appraisal of iodine refractory thyroid cancer.
    Vaisman F; Carvalho DP; Vaisman M
    Endocr Relat Cancer; 2015 Dec; 22(6):R301-10. PubMed ID: 26307020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multikinase inhibitors in thyroid cancer.
    Licitra L; Locati LD; Greco A; Granata R; Bossi P
    Eur J Cancer; 2010 Apr; 46(6):1012-8. PubMed ID: 20171085
    [TBL] [Abstract][Full Text] [Related]  

  • 5. B-RAF mutations in the etiopathogenesis, diagnosis, and prognosis of thyroid carcinomas.
    Trovisco V; Soares P; Sobrinho-Simões M
    Hum Pathol; 2006 Jul; 37(7):781-6. PubMed ID: 16784975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BRAF is a therapeutic target in aggressive thyroid carcinoma.
    Salvatore G; De Falco V; Salerno P; Nappi TC; Pepe S; Troncone G; Carlomagno F; Melillo RM; Wilhelm SM; Santoro M
    Clin Cancer Res; 2006 Mar; 12(5):1623-9. PubMed ID: 16533790
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Bcl-2 antisense oligonucleotide on drug-sensitivity in association with apoptosis in undifferentiated thyroid carcinoma.
    Kim R; Tanabe K; Uchida Y; Emi M; Toge T
    Int J Mol Med; 2003 Jun; 11(6):799-804. PubMed ID: 12736725
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Significance of BRAF mutations in papillary thyroid carcinoma: prognostic and therapeutic implications.
    Groussin L; Fagin JA
    Nat Clin Pract Endocrinol Metab; 2006 Apr; 2(4):180-1. PubMed ID: 16932278
    [No Abstract]   [Full Text] [Related]  

  • 9. The role of BRAF-targeted therapy in astrocytomas: a review.
    Lang SS
    Neurosurgery; 2013 Aug; 60 Suppl 1():110-2. PubMed ID: 23839361
    [No Abstract]   [Full Text] [Related]  

  • 10. Targeted therapy for thyroid cancer: striking the survival signaling.
    Vitale M
    J Clin Endocrinol Metab; 2011 Apr; 96(4):936-8. PubMed ID: 21474689
    [No Abstract]   [Full Text] [Related]  

  • 11. [Genetic causes of the thyroid carcinomas].
    Jindrichová S; Vlcek P; Bendlová B
    Cas Lek Cesk; 2004; 143(10):664-8. PubMed ID: 15584614
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New insights in thyroid follicular cell biology and its impact in thyroid cancer therapy.
    Riesco-Eizaguirre G; Santisteban P
    Endocr Relat Cancer; 2007 Dec; 14(4):957-77. PubMed ID: 18045949
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular genetics of thyroid cancer: implications for diagnosis, treatment and prognosis.
    Nikiforova MN; Nikiforov YE
    Expert Rev Mol Diagn; 2008 Jan; 8(1):83-95. PubMed ID: 18088233
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced B-Raf protein expression is independent of V600E mutant status in thyroid carcinomas.
    Kondo T; Nakazawa T; Murata S; Kurebayashi J; Ezzat S; Asa SL; Katoh R
    Hum Pathol; 2007 Dec; 38(12):1810-8. PubMed ID: 17714762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thyroid cancer review 3: management of medullary and undifferentiated thyroid cancer.
    Nix PA; Nicolaides A; Coatesworth AP
    Int J Clin Pract; 2006 Jan; 60(1):80-4. PubMed ID: 16409432
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aberrant BRAF splicing as an alternative mechanism for oncogenic B-Raf activation in thyroid carcinoma.
    Baitei EY; Zou M; Al-Mohanna F; Collison K; Alzahrani AS; Farid NR; Meyer B; Shi Y
    J Pathol; 2009 Apr; 217(5):707-15. PubMed ID: 19156774
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Molecular-targeted therapy for thyroid cancer: from bench to bedside].
    Mitsutake N
    Nihon Rinsho; 2011 Mar; 69 Suppl 2():376-80. PubMed ID: 21830570
    [No Abstract]   [Full Text] [Related]  

  • 18. Molecular profile of hyalinizing trabecular tumours of the thyroid: high prevalence of RET/PTC rearrangements and absence of B-raf and N-ras point mutations.
    Salvatore G; Chiappetta G; Nikiforov YE; Decaussin-Petrucci M; Fusco A; Carney JA; Santoro M
    Eur J Cancer; 2005 Mar; 41(5):816-21. PubMed ID: 15763659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of a novel B-Raf fusion protein related to c-Met drug resistance.
    Dillon R; Nilsson CL; Shi SD; Lee NV; Krastins B; Greig MJ
    J Proteome Res; 2011 Nov; 10(11):5084-94. PubMed ID: 21936566
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acquisition of BRAF gene mutations is not a requirement for nodal metastasis of papillary thyroid carcinoma.
    Trovisco V; Couto JP; Cameselle-Teijeiro J; de Castro IV; Fonseca E; Soares P; Sobrinho-Simões M
    Clin Endocrinol (Oxf); 2008 Oct; 69(4):683-5. PubMed ID: 18363883
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.